{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:17:32Z","timestamp":1791145052914,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.thromres.2014.11.006","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T13:23:00Z","timestamp":1416230580000},"page":"272-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms"],"prefix":"10.1016","volume":"135","author":[{"given":"Martyna","family":"Borowczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Wojtaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lewandowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Lehmann-Kopyd\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Kroll-Balcerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Balcerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Iwo\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieczys\u0142aw","family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.11.006_bb0005","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.thromres.2014.11.006_bb0015","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2014.11.006_bb0020","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.006_bb0035","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2014.11.006_bb0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0060","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.006_bb0065","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0070","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2014.11.006_bb0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0085","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404755","article-title":"The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis","volume":"21","author":"Pemmaraju","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2014.11.006_bb0090","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2014.11.006_bb0095","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jth.12265","article-title":"Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management","volume":"11","author":"Casini","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.006_bb0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0105","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/gtmb.2012.0366","article-title":"Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples","volume":"17","author":"Collier","year":"2013","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.thromres.2014.11.006_bb0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1155\/2013\/242045","article-title":"Dyspnea, massive effusion and lytic rib lesion as initial presentation of multiple myeloma in a young man","volume":"20","author":"Alshati","year":"2013","journal-title":"Can Respir J"},{"key":"10.1016\/j.thromres.2014.11.006_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations","volume":"160","author":"Bench","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.thromres.2014.11.006_bb0130","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20years. Gruppo Italiano Studio Policitemia","volume":"123","author":"Policitemia","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1538-7836.2011.04564.x","article-title":"Isolated distal deep vein thrombosis: what we know and what we are doing","volume":"10","author":"Palareti","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.006_bb0140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis","volume":"334","author":"Levine","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcu.20236","article-title":"Current approaches and controversial issues in the diagnosis of deep vein thrombosis via duplex Doppler ultrasound","volume":"34","author":"Gaitini","year":"2006","journal-title":"J Clin Ultrasound"},{"key":"10.1016\/j.thromres.2014.11.006_bb0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/asheducation.V2012.1.561.3807838","article-title":"The spectrum of JAK2-positive myeloproliferative neoplasms","volume":"2012","author":"Kiladjian","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.thromres.2014.11.006_bb0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2011","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.thromres.2014.11.006_bb0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0165","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0170","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb9000","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5045\/br.2013.48.2.128","article-title":"The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm","volume":"48","author":"Park","year":"2013","journal-title":"Blood Res."},{"key":"10.1016\/j.thromres.2014.11.006_bb9005","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2014.11.006_bb9010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2014.11.006_bb9015","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2013.74","article-title":"Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.thromres.2014.11.006_bb9020","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I, treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2014.11.006_bb9025","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3324\/haematol.2013.086348","article-title":"Advances in myelofibrosis: a clinical case approach","volume":"98","author":"Mascarenhas","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.thromres.2014.11.006_bb0175","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2014.11.006_bb0180","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3324\/haematol.2011.053348","article-title":"Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera","volume":"97","author":"Kuriakose","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0185","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2014.11.006_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.thromres.2014.11.006_bb0200","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain","volume":"93","author":"Ziakas","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.006_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2008.001271","article-title":"Clinical relevance of JAK2 (V617F) mutant allele burden","volume":"94","author":"Passamonti","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0210","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0220","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1538-7836.2005.01393.x","article-title":"Site and clinical outcome of deep vein thrombosis of the lower limbs: an epidemiological study","volume":"3","author":"Seinturier","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.006_bb0225","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.thromres.2014.02.033","article-title":"Unprovoked proximal venous thrombosis is associated with an increased risk of asymptomatic pulmonary embolism","volume":"133","author":"Boc","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.006_bb0230","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0235","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.thromres.2014.11.006_bb0245","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0250","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","article-title":"Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study","volume":"90","author":"Palandri","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0255","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0260","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0265","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0270","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0275","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s002770000244","article-title":"The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia","volume":"80","author":"Jantunen","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0280","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0285","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2014.11.006_bb0290","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0295","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2013-07-515676","article-title":"JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb0300","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.13074","article-title":"The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders","volume":"93","author":"Theocharides","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0305","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3324\/haematol.2009.021444","article-title":"Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia","volume":"95","author":"Antonioli","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/102453309X385188","article-title":"Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.thromres.2014.11.006_bb0315","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3324\/haematol.13081","article-title":"Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy","volume":"93","author":"Girodon","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0320","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3324\/haematol.12801","article-title":"Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia","volume":"93","author":"Ricksten","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.006_bb0325","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08467.x","article-title":"Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients","volume":"152","author":"Besses","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0330","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.23417","article-title":"Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0335","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2014.11.006_bb0340","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score","volume":"8","author":"Barbar","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.006_bb0345","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3324\/haematol.12604","article-title":"Prevention of thrombosis in polycythemia vera and essential thrombocythemia","volume":"93","author":"Landolfi","year":"2008","journal-title":"Haematologica"},{"issue":"2 Suppl","key":"10.1016\/j.thromres.2014.11.006_bb0350","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.006_bb0355","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12325-010-0107-5","article-title":"Merino wool graduated compression stocking increases lower limb venous blood flow: a randomized controlled trial","volume":"28","author":"Charles","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.thromres.2014.11.006_bb0360","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1401468","article-title":"Prophylaxis against venous thromboembolism in ambulatory patients with cancer","volume":"370","author":"Connors","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0365","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/leu.2011.314","article-title":"Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera","volume":"26","author":"Reikvam","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2014.11.006_bb0370","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ejh.12275","article-title":"External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients","volume":"92","author":"Fu","year":"2014","journal-title":"European journal of haematology."},{"key":"10.1016\/j.thromres.2014.11.006_bb0375","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.006_bb0380","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.thromres.2014.11.006_bb0385","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2014.11.006_bb0390","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms","volume":"27","author":"Bhagwat","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.006_bb7000","doi-asserted-by":"crossref","first-page":"e8893","DOI":"10.1371\/journal.pone.0008893","article-title":"Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients","volume":"5","author":"Ugo","year":"2010","journal-title":"PloS one."},{"key":"10.1016\/j.thromres.2014.11.006_bb6000","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1160\/TH09-01-0053","article-title":"Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study","volume":"102","author":"Galanaud","year":"2009","journal-title":"Thrombosis and haemostasis."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481400615X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481400615X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T23:09:53Z","timestamp":1598483393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938481400615X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S004938481400615X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.006","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}